Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Chairman, CEO, and Interim CFO Pham Quang X executed a series of stock sales totaling $93,293 between June 8 and June 10, 2026. The transactions, involving 22,385 shares priced between $4.03 and $4.51, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. This activity occurs as the company navigates post-Phase 2 regulatory milestones and financial restructuring efforts.
The execution of these sales was structured across three distinct trading days. On June 8, Mr. Pham liquidated 5,893 shares at a weighted average price of $4.38, with individual transaction prices spanning from $4.20 to $4.51. The following day, June 9, the insider sold an additional 12,992 shares at a weighted average price of $4.06, with prices ranging from $4.03 to $4.34. The final tranche on June 10 involved the sale of 3,500 shares at a weighted average price of $4.21, with prices tightly clustered between $4.20 and $4.23.
Following these divestitures, Mr. Pham's direct holdings in Cadrenal Therapeutics common stock stand at 150,839 shares. Indirect ownership remains significant through The PVBQ Living Trust, where he serves as Trustee with sole voting and dispositive power, and his child acts as the sole beneficiary, holding an additional 200,000 shares. As a director and ten percent owner, Mr. Pham retains substantial equity exposure despite the recent liquidation activity.
The sales transpire against a backdrop of depressed equity valuation, with the stock trading near its 52-week low of $3.90. Shares have declined 72% over the past year, reflecting broader market pressures on the biotechnology sector. Despite the poor performance, InvestingPro analysis suggests the stock may be undervalued at current levels, with 13 additional ProTips available to subscribers.
On the operational front, Cadrenal Therapeutics recently reported a net loss of $3.0 million for the fourth quarter ending December 31, 2025. This figure marks an improvement from the $4.2 million loss recorded in the same period of 2024. The company has completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration and received guidance to advance CAD-1005 to a pivotal Phase 3 trial for the treatment of heparin-induced thrombocytopenia.
Regulatory guidance includes specific parameters on protocol design, study population, dosing, background therapy, and the primary endpoint of new or worsening thrombotic events. Cadrenal plans to conduct a randomized, blinded, placebo-controlled Phase 3 study enrolling approximately 120 patients globally. The results of this trial are intended to support a New Drug Application submission projected for 2029. The company is actively incorporating the FDA's feedback into its Phase 3 protocol. These developments reflect Cadrenal's ongoing efforts to advance its investigational treatments in collaboration with regulatory authorities.
Market data indicates CVKD closed at $4.14, reflecting a gain of 0.1900 (+4.81%). After-hours trading showed the stock at $4.22, up 0.0800 (+1.93%). The stock's volatility highlights the sensitivity of small-cap biotech equities to both corporate milestones and broader macroeconomic conditions.